Physician profile
Michael Schultz
NPI 1396727533
$5,147.84
in general payments reported to CMS, 2019-2025
22 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $83.68 · 2023: $1,033 · 2024: $1,864 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,829 · Education: $68.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.92 |
| Education | $68.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.56 | 2021-2025 | |
| Janssen Biotech, INC. | $590.79 | 2023-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $498.14 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $367.71 | 2023-2025 | Ibsrela |
| Pfizer INC. | $298.37 | 2023-2025 | |
| Gilead Sciences, INC. | $285.60 | 2021-2025 | |
| Genzyme Corporation | $226.34 | 2023-2024 | |
| Qol Medical, LLC | $190.01 | 2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $188.95 | 2024-2025 | Voquezna |
| Celgene Corporation | $187.18 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $177.56 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.47 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Regeneron Healthcare Solutions, INC. | $137.35 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $127.70 | 2024-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $98.11 | 2025 | Rezdiffra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $94.27 | 2023-2024 | Linzess |
| Vivus LLC | $63.54 | 2025 | Pancreaze, Qsymia |
| Aimmune Therapeutics, INC. | $53.64 | 2024-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $44.72 | 2023 | |
| Lilly USA, LLC | $42.88 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $35.47 | 2024 | Zymfentra |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.